September 16, 2017 – By Hazel Jackson
Why Has RBC Capital Markets Given Athenex (UNKNOWN:ATNX) a $35.00 Price Target
RBC Capital Markets sent to clients and investors in a report that it has initiated coverage on Athenex (UNKNOWN:ATNX) stock, with “Outperform” rating and a $35.00 target price.
The stock increased 2.81% or $0.46 on September 15, reaching $16.84. About 1.00 million shares traded or 647.49% up from the average. Athenex Inc (UNKNOWN:ATNX) has 0.00% since September 16, 2016 and is . It has underperformed by 16.70% the S&P500.
Athenex, Inc. is an oncology pharmaceutical firm focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The company has market cap of $960.95 million. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. It currently has negative earnings. The Firm offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers.
More notable recent Athenex Inc (NASDAQ:ATNX) news were published by: Globenewswire.com which released: “Athenex, Inc. Announces Submission of Investigational New Drug Application of …” on July 05, 2017, also Marketwatch.com with their article: “16.84” published on May 17, 2017, Nasdaq.com published: “Athenex, Inc. Announces Second Quarter 2017 Results” on August 14, 2017. More interesting news about Athenex Inc (NASDAQ:ATNX) were released by: Globenewswire.com and their article: “Athenex, Inc. Announces Approval of Tax Incentives from State of New York for …” published on July 27, 2017 as well as Globenewswire.com‘s news article titled: “Athenex, Inc. Announces Commencement of Patient Enrollment for Oraxol-plus …” with publication date: July 19, 2017.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.